Seres Therapeutics
Market Cap
US$2.2b
Last Updated
2021/01/25 23:26 UTC
Data Sources
Company Financials +
Executive Summary
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Seres Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MCRB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: MCRB's weekly volatility has decreased from 56% to 10% over the past year.
Market Performance
7 Day Return
1.5%
MCRB
1.8%
US Biotechs
2.3%
US Market
1 Year Return
671.4%
MCRB
45.9%
US Biotechs
23.8%
US Market
Return vs Industry: MCRB exceeded the US Biotechs industry which returned 45.9% over the past year.
Return vs Market: MCRB exceeded the US Market which returned 23.8% over the past year.
Shareholder returns
| MCRB | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | 1.8% | 2.3% |
| 30 Day | 2.3% | 6.7% | 4.8% |
| 90 Day | -17.8% | 26.1% | 16.7% |
| 1 Year | 671.4%671.4% | 48.3%45.9% | 26.6%23.8% |
| 3 Year | 126.8%126.8% | 23.3%16.6% | 45.0%35.4% |
| 5 Year | -5.2%-5.2% | 58.9%46.7% | 126.2%101.0% |
Long-Term Price Volatility Vs. Market
How volatile is Seres Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Is There An Opportunity With Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 32% Undervaluation?2 months ago | Simply Wall St
What Does The Future Hold For Seres Therapeutics, Inc. (NASDAQ:MCRB)? These Analysts Have Been Cutting Their Estimates2 months ago | Simply Wall St
Seres Therapeutics, Inc. (NASDAQ:MCRB) Just Reported And Analysts Have Been Cutting Their EstimatesValuation
Is Seres Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MCRB ($24.05) is trading below our estimate of fair value ($209.27)
Significantly Below Fair Value: MCRB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MCRB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MCRB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MCRB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MCRB is overvalued based on its PB Ratio (11.7x) compared to the US Biotechs industry average (4.4x).
Next Steps
Future Growth
How is Seres Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
45.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MCRB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MCRB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MCRB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MCRB's revenue (52.5% per year) is forecast to grow faster than the US market (10.6% per year).
High Growth Revenue: MCRB's revenue (52.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MCRB's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Seres Therapeutics performed over the past 5 years?
-2.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MCRB is currently unprofitable.
Growing Profit Margin: MCRB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MCRB is unprofitable, and losses have increased over the past 5 years at a rate of 2.9% per year.
Accelerating Growth: Unable to compare MCRB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MCRB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: MCRB has a negative Return on Equity (-47.67%), as it is currently unprofitable.
Next Steps
Financial Health
How is Seres Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: MCRB's short term assets ($308.0M) exceed its short term liabilities ($45.8M).
Long Term Liabilities: MCRB's short term assets ($308.0M) exceed its long term liabilities ($122.4M).
Debt to Equity History and Analysis
Debt Level: MCRB's debt to equity ratio (13.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MCRB's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MCRB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MCRB has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 25.7% each year.
Next Steps
Dividend
What is Seres Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MCRB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MCRB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MCRB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MCRB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MCRB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Eric Shaff (44 yo)
2yrs
Tenure
US$2,032,548
Compensation
Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer of Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...
CEO Compensation Analysis
Compensation vs Market: Eric's total compensation ($USD2.03M) is below average for companies of similar size in the US market ($USD3.85M).
Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2yrs | US$2.03m | no data | |
| Executive VP & Chief Scientific Officer | 1.92yrs | US$859.45k | 0% $ 0 | |
| Chief Legal Officer | 4.67yrs | US$977.34k | 0% $ 0 | |
| Senior VP of Finance and Principal Financial & Accounting Officer | 3yrs | no data | 0.0094% $ 206.7k | |
| Executive VP & Chief Technology Officer | 0.25yr | no data | no data | |
| VP of Investor Relations & Corporate Communications | 5.17yrs | no data | no data | |
| Vice President of Human Resources | 3.67yrs | no data | no data | |
| Executive VP & Chief People Officer | 0.25yr | no data | no data | |
| Senior Advisor | 0.25yr | no data | 0.12% $ 2.5m | |
| Senior Vice President of Regulatory Affairs | 3.67yrs | no data | no data | |
| Executive VP & Chief Medical Officer | 0.83yr | no data | no data | |
| Executive VP and Chief Commercial & Strategy Officer | 0.58yr | no data | no data |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Management: MCRB's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2yrs | US$2.03m | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.5yrs | US$75.65k | 0% $ 0 | |
| Independent Director | 5.75yrs | US$69.23k | 0% $ 0 | |
| Independent Director | 5.17yrs | US$78.15k | 0% $ 0 | |
| Independent Director | 6.25yrs | US$88.15k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6yrs | no data | no data | |
| Independent Director | 6.08yrs | US$71.65k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman | 1.08yrs | US$62.76k | 0.0039% $ 86.2k |
5.5yrs
Average Tenure
61.5yo
Average Age
Experienced Board: MCRB's board of directors are considered experienced (5.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.4%.
Top Shareholders
Company Information
Seres Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Seres Therapeutics, Inc.
- Ticker: MCRB
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.195b
- Shares outstanding: 91.25m
- Website: https://www.serestherapeutics.com
Number of Employees
Location
- Seres Therapeutics, Inc.
- 200 Sidney Street
- 4th Floor
- Cambridge
- Massachusetts
- 2139
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MCRB | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Jun 2015 |
| 1S9 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jun 2015 |
Biography
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The com...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/25 23:26 |
| End of Day Share Price | 2021/01/25 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.